Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
The Hospital Acquired Pneumonia Drugs in Development market research report provides an in-depth analysis of the Hospital Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.
Hospital Acquired Pneumonia Pipeline Drugs Market Targets
The targets of the Hospital Acquired Pneumonia pipeline drugs market are Beta Lactamase, Penicillin Binding Protein, Bacterial Cell Membrane, Lipopolysaccharide, Peptidoglycan, 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein 2, Staphylococcus aureus Alpha Hemolysin, and Bacterial Cell Wall.
Hospital Acquired Pneumonia Pipeline Drugs Market, By Targets
For more target insights, download a free report sample
Mechanisms of Action of Hospital Acquired Pneumonia Pipeline Drugs Market
The mechanisms of action of the Hospital Acquired Pneumonia pipeline drugs market are Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, Bacterial Cell Membrane Disruptor, Lipopolysaccharide Inhibitor, Peptidoglycan Inhibitor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein 2 Inhibitor, Staphylococcus aureus Alpha Hemolysin Inhibitor, and Bacterial Cell Wall Disruptor.
Hospital Acquired Pneumonia Pipeline Drugs Market, By Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Hospital Acquired Pneumonia Pipeline Drugs Market
The routes of administration in the Hospital Acquired Pneumonia pipeline drugs market are intravenous, inhalational, oral, topical, intraarticular, intradermal, intravenous drip, nasal, ophthalmic, and vaginal.
Hospital Acquired Pneumonia Pipeline Drugs Market, By Routes of Administration
For more routes of administration insights, download a free report sample
Molecule Types in Hospital Acquired Pneumonia Pipeline Drugs Market
The molecule types in the Hospital Acquired Pneumonia pipeline drugs market are small molecule, monoclonal antibody, peptide, biologic, synthetic peptide, cell therapy, polysaccharide, protein, and recombinant enzyme.
Hospital Acquired Pneumonia Pipeline Drugs Market, By Molecule Types
For more molecule type insights, download a free report sample
Key Hospital Acquired Pneumonia Pipeline Drugs Market Companies
Some of the key companies in the Hospital Acquired Pneumonia pipeline drugs market are Aridis Pharmaceuticals Inc, Helperby Therapeutics Group Ltd, Wockhardt Ltd, Destiny Pharma Plc, Meiji Seika Pharma Co Ltd, Nabriva Therapeutics Plc, Pfizer Inc, Spexis AG, AiCuris AG, and Allecra Therapeutics GmbH.
Hospital Acquired Pneumonia Pipeline Drugs Market, By Key Companies
To know more about key companies, download a free report sample
Market report overview
Targets | Beta Lactamase, Penicillin Binding Protein, Bacterial Cell Membrane, Lipopolysaccharide, Peptidoglycan, 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein 2, Staphylococcus aureus Alpha Hemolysin, and Bacterial Cell Wall |
Mechanisms of Action | Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, Bacterial Cell Membrane Disruptor, Lipopolysaccharide Inhibitor, Peptidoglycan Inhibitor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein 2 Inhibitor, Staphylococcus aureus Alpha Hemolysin Inhibitor, and Bacterial Cell Wall Disruptor |
Routes of Administration | Intravenous, Inhalational, Oral, Topical, Intraarticular, Intradermal, Intravenous Drip, Nasal, Ophthalmic, and Vaginal |
Molecule Types | Small Molecule, Monoclonal Antibody, Peptide, Biologic, Synthetic Peptide, Cell Therapy, Polysaccharide, Protein, and Recombinant Enzyme |
Key Companies | Aridis Pharmaceuticals Inc, Helperby Therapeutics Group Ltd, Wockhardt Ltd, Destiny Pharma Plc, Meiji Seika Pharma Co Ltd, Nabriva Therapeutics Plc, Pfizer Inc, Spexis AG, AiCuris AG, and Allecra Therapeutics GmbH |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- Reviews of pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- Evaluation of Hospital Acquired Pneumonia (Infectious Disease) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Hospital Acquired Pneumonia (HAP) (Infectious Disease). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Allecra Therapeutics GmbH
Antabio SAS
Aridis Pharmaceuticals Inc
Biolytx Pharmaceuticals Corp
Bioversys AG
Cellular Biomedicine Group Inc
Centauri Therapeutics Ltd
Clarametyx Biosciences Inc
ContraFect Corp
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
Eldec Pharmaceuticals Inc
Entasis Therapeutics Holdings Inc
Evotec SE
GangaGen Biotechnologies Pvt Ltd
Helperby Therapeutics Group Ltd
Hoth Therapeutics Inc
Hypo-Stream Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Nabriva Therapeutics Plc
Nosopharm SAS
Omnix Medical Ltd
Peptineo
Pfizer Inc
Pherecydes Pharma SA
Phico Therapeutics Ltd
Pulmobiotics SL
Qilu Pharmaceutical Co Ltd
Revagenix Inc
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Hospital Acquired Pneumonia pipeline drugs market?
The targets of the Hospital Acquired Pneumonia pipeline drugs market are Beta Lactamase, Penicillin Binding Protein, Bacterial Cell Membrane, Lipopolysaccharide, Peptidoglycan, 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein 2, Staphylococcus aureus Alpha Hemolysin, and Bacterial Cell Wall.
-
What are the mechanisms of action of the Hospital Acquired Pneumonia pipeline drugs market?
The mechanisms of action of the Hospital Acquired Pneumonia pipeline drugs market are Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, Bacterial Cell Membrane Disruptor, Lipopolysaccharide Inhibitor, Peptidoglycan Inhibitor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein 2 Inhibitor, Staphylococcus aureus Alpha Hemolysin Inhibitor, and Bacterial Cell Wall Disruptor.
-
What are the routes of administration in the Hospital Acquired Pneumonia pipeline drugs market?
The routes of administration in the Hospital Acquired Pneumonia pipeline drugs market are intravenous, inhalational, oral, topical, intraarticular, intradermal, intravenous drip, nasal, ophthalmic, and vaginal.
-
What are the molecule types in the Hospital Acquired Pneumonia pipeline drugs market?
The molecule types in the Hospital Acquired Pneumonia pipeline drugs market are small molecule, monoclonal antibody, peptide, biologic, synthetic peptide, cell therapy, polysaccharide, protein, and recombinant enzyme.
-
Which are the key companies in the Hospital Acquired Pneumonia pipeline drugs market?
Some of the key companies in the Hospital Acquired Pneumonia pipeline drugs market are Aridis Pharmaceuticals Inc, Helperby Therapeutics Group Ltd, Wockhardt Ltd, Destiny Pharma Plc, Meiji Seika Pharma Co Ltd, Nabriva Therapeutics Plc, Pfizer Inc, Spexis AG, AiCuris AG, and Allecra Therapeutics GmbH.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.